Business
Cytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming poster presentations
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming poster presentations at the American Heart Association Scientific Sessions 2022 taking place in Chicago, IL from November 5, 2022 - November 7, 2022. The poster presentations include an analysis of patients hospitalized for heart failure with severely reduced ejection fraction from the Get With The Guidelines®-Heart Failure Registry as well as two analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), one relating to healthcare resource use, early benefit, and cost for North American patients most likely to benefit from treatment with omecamtiv mecarbil, and one assessing sex differences in GALACTIC-HF. Title: Clinical Profile of Patients Hospitalized for Heart Failure with Severely Reduced Ejection Fraction: From the GWTG-HF RegistryPresenter: Stephen Greene, M.D., Assistant Professor, Division of Cardiology, Advanced Heart Failure and Transplantation, Duke University Medical Center, Duke Clinical Research InstituteDate: November 5, 2022Session Title: Heart Failure Across the Spectrum of EFBoard Number: 2195Session Time: 3:00 PM – 4:00 PM CTLocation: Zone 2‚ Science and Technology Hall‚ Level 3 Title: Healthcare Resource Use, Early Benefit and Cost for North American Patients with HFrEF Most Likely to Benefit from Omecamtiv MecarbilPresenter: Nihar R. Desai, M.D., MPH, Associate Professor of Medicine, Associate Chief, Cardiovascular Medicine, Yale School of Medicine, Center for Outcomes Research and EvaluationDate: November 7, 2022Session Title: Heart Failure Management on Populations and Outcomes ResearchBoard Number: 2106Session Time: 11:00 AM – 12:00 PM CTLocation: Zone 2‚ Science and Technology Hall‚ Level 3 Title: Sex Differences in Heart Failure with Reduced Ejection Fraction in the GALACTIC-HF TrialPresenter: Maria Pabon Porras, M.D., Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical SchoolDate: November 7, 2022Session Title: Heart Failure Management on Populations and Outcomes ResearchBoard Number: 2103Session Time: 11:00 AM – 12:00 PM CTLocation: Zone 2‚ Science and Technology Hall‚ Level 3 About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, ...